Cargando…

Comparison of the efficacy and risk of discontinuation between non-TNF-targeted treatment and a second TNF inhibitor in patients with rheumatoid arthritis after first TNF inhibitor failure

OBJECTIVES: Despite improved care for rheumatoid arthritis (RA) patients, many still experience treatment failure with biologic disease-modifying antirheumatic drugs (bDMARDs) or targeted synthetic DMARDs [tsDMARDs; typically Janus kinase inhibitors (JAKi)], and eventually switch to other agents. We...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Dong-Jin, Choi, Sung-Eun, Kang, Ji-Hyoun, Shin, Kichul, Sung, Yoon-Kyoung, Lee, Shin-Seok
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021479/ https://www.ncbi.nlm.nih.gov/pubmed/35464808 http://dx.doi.org/10.1177/1759720X221091450

Ejemplares similares

Discontinuation rates of biologics in patients with rheumatoid arthritis: are TNF inhibitors different from non-TNF inhibitors?
por: Ramiro, Sofia, et al.
Publicado: (2015)

Drug retention and safety of TNF inhibitors in elderly patients with rheumatoid arthritis
por: Cho, Soo-Kyung, et al.
Publicado: (2016)

Cost Effectiveness of TNF-α Inhibitors in Rheumatoid Arthritis
por: Said, Cynthia, et al.
Publicado: (2013)

Baseline bony erosions and time-averaged DAS28 predict discontinuation of TNF inhibitors in rheumatoid arthritis
por: Min, Hong Ki, et al.
Publicado: (2022)

ADAM17 Genetic Variants and the Response of TNF-α Inhibitor in Rheumatoid Arthritis Patients
por: Kim, Hyun Jeong, et al.
Publicado: (2020)

Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort
por: Ciurea, Adrian, et al.
Publicado: (2016)

Discontinuation of tofacitinib and TNF inhibitors in patients with rheumatoid arthritis: analysis of pooled data from two registries in Canada
por: Movahedi, Mohammad, et al.
Publicado: (2023)

Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFα blocker failure
por: Kekow, Joern, et al.
Publicado: (2012)

Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis
por: Lopez-Rodriguez, Rosario, et al.
Publicado: (2018)

Aggrecan Turnover in Women with Rheumatoid Arthritis Treated with TNF-α Inhibitors
por: Szeremeta, Anna, et al.
Publicado: (2020)

Methotrexate Reduces the Probability of Discontinuation of TNF Inhibitors in Seropositive Patients With Rheumatoid Arthritis. A Real-World Data Analysis
por: Hernández-Breijo, Borja, et al.
Publicado: (2021)

Comparative risk of infections between JAK inhibitors versus TNF inhibitors among patients with rheumatoid arthritis: a cohort study
por: Choi, Se Rim, et al.
Publicado: (2023)

TNF inhibitors increase the risk of nontuberculous mycobacteria in patients with seropositive rheumatoid arthritis in a mycobacterium tuberculosis endemic area
por: Park, Dong Won, et al.
Publicado: (2022)

New approaches to inhibiting TNF production in rheumatoid arthritis: is pathological TNF regulated in the same way as protective TNF?
por: Feldmann, M, et al.
Publicado: (2001)

TNF-α and TNF-β Gene Polymorphism in Saudi Rheumatoid Arthritis Patients
por: Al-Rayes, Hannan, et al.
Publicado: (2011)

The Effect of TNF and Non-TNF-Targeted Biologics on Body Composition in Rheumatoid Arthritis
por: Vial, Gaelle, et al.
Publicado: (2021)

Use of TNF Inhibitors in Rheumatoid Arthritis and Implications for the Periodontal Status: For the Benefit of Both?
por: Zamri, Fatima, et al.
Publicado: (2020)

What Is the Clinical Relevance of TNF Inhibitor Immunogenicity in the Management of Patients With Rheumatoid Arthritis?
por: Mehta, Puja, et al.
Publicado: (2020)

Cardiovascular Risk Associated With TNF Alpha Inhibitor Use in Patients With Rheumatoid Arthritis
por: Hussain, Aaiz, et al.
Publicado: (2021)

BAFF predicts immunogenicity in older patients with rheumatoid arthritis treated with TNF inhibitors
por: Hernández-Breijo, Borja, et al.
Publicado: (2021)

Disease activity in axial spondyloarthritis after discontinuation of TNF inhibitors therapy
por: Sebastian, Agata, et al.
Publicado: (2017)

Immunogenicity of TNF-Inhibitors
por: Atiqi, Sadaf, et al.
Publicado: (2020)

Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis
por: Huoponen, Saara, et al.
Publicado: (2019)

Anti-TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF–TNF-RII binding in rheumatoid arthritis
por: Nguyen, Dao Xuan, et al.
Publicado: (2016)

The risk of newly diagnosed cancer in patients with rheumatoid arthritis by TNF inhibitor use: a nationwide cohort study
por: Choi, Boyoon, et al.
Publicado: (2022)

Structural Biology of the TNFα Antagonists Used in the Treatment of Rheumatoid Arthritis
por: Lim, Heejin, et al.
Publicado: (2018)

Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis
por: Nakashita, Tamao, et al.
Publicado: (2014)

Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab
por: Neovius, M, et al.
Publicado: (2015)

Exploring the Inflammatory Metabolomic Profile to Predict Response to TNF-α Inhibitors in Rheumatoid Arthritis
por: Cuppen, Bart V. J., et al.
Publicado: (2016)

Blood Lymphocyte Subsets for Early Identification of Non-Remission to TNF Inhibitors in Rheumatoid Arthritis
por: Rodríguez-Martín, Eulalia, et al.
Publicado: (2020)

Therapeutic monitoring of TNF inhibitors for rheumatoid arthritis: evidence required following NICE’s recommendations
por: Gavan, Sean P, et al.
Publicado: (2020)

Bone and TNF in rheumatoid arthritis: clinical implications
por: Manara, Maria, et al.
Publicado: (2015)

Safe Re-administration of Tumor Necrosis Factor-alpha (TNFα) Inhibitors in Patients with Rheumatoid Arthritis or Ankylosing Spondylitis Who Developed Active Tuberculosis on Previous Anti-TNFα Therapy
por: Suh, Young Sun, et al.
Publicado: (2014)

Hepatorenal pathologies in TNF-transgenic mouse model of rheumatoid arthritis are alleviated by anti-TNF treatment
por: Li, Xuefei, et al.
Publicado: (2023)

Correction: The risk of newly diagnosed cancer in patients with rheumatoid arthritis by TNF inhibitor use: a nationwide cohort study
por: Choi, Boyoon, et al.
Publicado: (2022)

TNF-α inhibitors: are they carcinogenic?
por: Raval, Girindra, et al.
Publicado: (2010)

The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics
por: Jang, Dan-in, et al.
Publicado: (2021)

Factors for starting biosimilar TNF inhibitors in patients with rheumatic diseases in the real world
por: Sung, Yoon-Kyoung, et al.
Publicado: (2020)

Factors affecting drug survival of an alternative TNF inhibitor and secukinumab in patients with ankylosing spondylitis switching from the first TNF inhibitor
por: Kwon, Oh Chan, et al.
Publicado: (2021)

TNF inhibitors induce discoid fibrosis in the sublining layers of the synovium with degeneration of synoviocytes in rheumatoid arthritis
por: Hirohata, Shunsei, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_07fe5c9mu6njb44i84v7hjnic7